Literature DB >> 19214115

Patterns and predictors of adherence to diaphragm use in a phase III trial in sub-Saharan Africa: a trajectory analysis.

Ariane van der Straten1, Stephen Shiboski, Elizabeth T Montgomery, Jie Moore, Guy De Bruyn, Gita Ramjee, Agnes Chidanyika, Deborah Kacanek, Nancy Padian.   

Abstract

BACKGROUND: We examined diaphragm adherence among 2429 women randomized to the intervention arm (diaphragm + gel + condoms) in Methods for Improving Reproductive Health in Africa, a phase III trial of the diaphragm for HIV prevention in Zimbabwe and South Africa.
METHODS: Women were followed for a median of 7 quarterly visits (range: 1-8 quarterly visits) during which diaphragm adherence was assessed. We conducted trajectory analyses to identify behavioral groups associated with specific diaphragm adherence patterns. Multivariate multinomial logistic regression was used to identify baseline characteristics associated with higher probability of being in a particular trajectory group.
RESULTS: Diaphragm uptake was very high (3.1% never used diaphragms). However, diaphragm adherence was reported at only 49% of visits. Women were clustered into 4 diaphragm adherence groups based on their highest estimated group membership probability: low adherers (31.0%), decreasing adherers (28.9%), increasing adherers (9.3%), and high adherers (30.8%). Women classified as high adherers (as compared with low adherers) were more likely to be older [adjusted odds ratio (AOR) = 1.09, 95% confidence interval (CI): 1.07 to 1.11] and to report baseline condom adherence (AOR = 2.00, 95% CI: 1.47 to 2.71). They were less likely to have high-risk behavior (AOR = 0.51; 95% CI: 0.37 to 0.71) and to have high-risk partners (AOR = 0.58; 95% CI: 0.43 to 0.78). They were most likely to be from the Zimbabwe site (AOR = 2.82; 95% CI: 1.89 to 4.20) and least likely to be from the Johannesburg site (AOR = 0.51; 95% CI: 0.37 to 0.77).
CONCLUSION: This analytic approach could help to identify high compliers for enrollment in future HIV prevention trials or the types of participants who may need intensive adherence counseling during follow-up.

Entities:  

Mesh:

Year:  2009        PMID: 19214115     DOI: 10.1097/QAI.0b013e3181958511

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  11 in total

1.  Longitudinal HIV Care Trajectories in North Carolina.

Authors:  Kimberly A Powers; Erika Samoff; Mark A Weaver; Lynne A Sampson; William C Miller; Peter A Leone; Heidi Swygard
Journal:  J Acquir Immune Defic Syndr       Date:  2017-02-01       Impact factor: 3.731

2.  Trajectory of use over time of an oral tablet and a rectal gel for HIV prevention among transgender women and men who have sex with men.

Authors:  Cheng-Shiun Leu; Rebecca Giguere; José A Bauermeister; Curtis Dolezal; William Brown; Ivan C Balán; Barbra A Richardson; Jeanna M Piper; Javier R Lama; Ross D Cranston; Alex Carballo-Diéguez
Journal:  AIDS Care       Date:  2018-10-14

3.  Adherence to diaphragm use for infection prevention: a prospective study of female sex workers in Kenya.

Authors:  Elizabeth A Bukusi; Maria F Gallo; Anjali Sharma; Betty Njoroge; Denise J Jamieson; Rosemary Nguti; April J Bell; David A Eschenbach
Journal:  Infect Dis Obstet Gynecol       Date:  2010-03-07

4.  Change in condom and other barrier method use during and after an HIV prevention trial in Zimbabwe.

Authors:  Ariane van der Straten; Helen Cheng; Alexandra M Minnis
Journal:  J Int AIDS Soc       Date:  2010-10-19       Impact factor: 5.396

5.  The importance of male partner involvement for women's acceptability and adherence to female-initiated HIV prevention methods in Zimbabwe.

Authors:  Elizabeth T Montgomery; Ariane van der Straten; Agnes Chidanyika; Tsungai Chipato; Shabbar Jaffar; Nancy Padian
Journal:  AIDS Behav       Date:  2011-07

6.  Baseline Predictors of High Adherence to a Coitally Dependent Microbicide Gel Based on an Objective Marker of Use: Findings from the Carraguard Phase 3 Trial.

Authors:  Barbara A Friedland; Marie Stoner; Michelle M Chau; Marlena Gehret Plagianos; Sumen Govender; Neetha Morar; Lydia Altini; Stephanie Skoler-Karpoff; Khatija Ahmed; Gita Ramjee; Constance Monedi; Robin Maguire; Pekka Lähteenmäki
Journal:  AIDS Behav       Date:  2016-11

7.  Acceptability and use of the diaphragm and Replens lubricant gel for HIV prevention in Southern Africa.

Authors:  Elizabeth T Montgomery; Helen Cheng; Ariane van der Straten; Agnes C Chidanyika; Naomi Lince; Kelly Blanchard; Gita Ramjee; Busisiwe Nkala; Nancy S Padian
Journal:  AIDS Behav       Date:  2009-09-10

Review 8.  Adherence and its measurement in phase 2/3 microbicide trials.

Authors:  Elizabeth E Tolley; Polly F Harrison; Els Goetghebeur; Kathleen Morrow; Robert Pool; Doug Taylor; Stephanie N Tillman; Ariane van der Straten
Journal:  AIDS Behav       Date:  2010-10

9.  Diaphragm used with replens gel and risk of bacterial vaginosis: results from a randomized controlled trial.

Authors:  Craig R Cohen; Su-Chun Cheng; Stephen Shiboski; Tsungai Chipato; Martin Matu; James Mwangi; Monalisa E S Mutimutema; Jennifer Tuveson; Mavis Kamba; Nancy Padian; Ariane van der Straten
Journal:  Infect Dis Obstet Gynecol       Date:  2012-10-24

Review 10.  Microbicide clinical trial adherence: insights for introduction.

Authors:  Cynthia Woodsong; Kathleen MacQueen; K Rivet Amico; Barbara Friedland; Mitzy Gafos; Leila Mansoor; Elizabether Tolley; Sheena McCormack
Journal:  J Int AIDS Soc       Date:  2013-04-08       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.